Innovative solutions for the serological detection of HPV16 induced cancer
- a new Class of Immune Oncology Diagnostics
Extensive know-how and expertise in HPV diagnostics and our own cancer research led to 3 registered patent families and proprietary immunological components, which underpin the exceptional quality of Abviris test systems.
Key characteristics are:
- Only one drop of blood or serum needed to perform a systemic entire-body screen to detect HPV16-induced cancer
- Clinically proven specificity of over 99% and sensitivity of 95% (determined with > 5000 patients in multiple clinical trials)
- Results are available within minutes, right at point of care
- Robust test design and easy handling
- Patented and CE marked
Prevo-Check® is the first diagnostic test that enables entire-body screens for the early detection of these cancer types.